Annual Report for the financial year 2024-2025 is submitted.
DRAGARWQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Agarwal's Eye Hospital submitted its 31st Annual Report for FY 2024-25 to BSE on September 2, 2025, along with the notice for the 31st AGM scheduled for September 24, 2025, to be held via video conferencing with e-voting through CDSL. For FY2025, the company reported total income of ₹402 crore (up 24%), EBITDA of ₹124 crore (up 28.7%), and profit after tax of ₹55 crore (up 17.9%), treating over 5.88 lakh patients and performing 62,000+ surgeries across 63 facilities. The board has proposed a dividend of ₹3.50 per share (35%) for FY2024-25. The AGM notice also seeks shareholder approval for a preferential issue of 1,32,827 equity shares to promoter Dr. Agarwal's Health Care Limited at ₹5,270 per share, raising up to ₹70 crore, and for the reappointment of Dr. Amar Agarwal (Chairman & MD) and Dr. Athiya Agarwal (Whole-Time Director) with revised remuneration.
Routine regulatory filing for shareholders to review, but contains material items requiring voting approval: a ₹70 crore preferential share issue to the promoter (modest dilution of about 2.8% on expanded capital) and revised remuneration for the two promoter-directors, both needing special resolution support.